An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...
An FDA vaccine advisory committee meeting to discuss next season’s flu vaccine has been canceled, potentially delaying the ...
An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...
Each year, flu vaccines are tailored to match the most prevalent virus strains expected to circulate. Without an official ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...
AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...
Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...
1d
GlobalData on MSNSanofi’s Sarclisa combo approved in Japan for newly diagnosed MMSanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...
Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.
Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi. According to Enveda, ...
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results